Cysteine added variants of interleukin-3 and chemical modifications thereof
US5166322A · kind A · utility
201Cited by
24References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 21, 1989 |
| Grant date | Nov 24, 1992 |
| Priority date | — |
| Expiry date | Apr 21, 2009 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/141
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cysteine added variants ("CAVs") of interleukin-3 are provided having one or more cysteine residues substituted for selected naturally occurring amino acid residues, or inserted into the polypeptide sequence, and preferably being further modified by deletion of certain N-terminal amino acids. Such CAVs may be additionally modified by the coupling of sulfhydryl reactive compounds to the introduced cysteine residue(s) without loss of bioactivity to produce selected homogeneously modified IL-3 and improved pharmaceutical compositions containing the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.